Rodman & Renshaw began coverage on shares of Heron Therapeutics (NASDAQ:HRTX – Free Report) in a report issued on Thursday, Marketbeat reports. The brokerage issued a buy rating and a $7.00 price target on the biotechnology company’s stock.
A number of other equities research analysts have also recently commented on the company. Capital One Financial started coverage on Heron Therapeutics in a research note on Tuesday, April 23rd. They issued an overweight rating and a $6.00 target price on the stock. Needham & Company LLC reissued a buy rating and issued a $5.00 target price on shares of Heron Therapeutics in a research note on Thursday, May 16th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and an average price target of $6.00.
View Our Latest Stock Report on HRTX
Heron Therapeutics Stock Down 0.8 %
Heron Therapeutics (NASDAQ:HRTX – Get Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.06. The firm had revenue of $34.67 million during the quarter, compared to analysts’ expectations of $32.50 million. Analysts forecast that Heron Therapeutics will post -0.1 EPS for the current fiscal year.
Institutional Investors Weigh In On Heron Therapeutics
Institutional investors have recently modified their holdings of the business. Headlands Technologies LLC purchased a new stake in shares of Heron Therapeutics during the first quarter valued at $30,000. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Heron Therapeutics during the first quarter valued at $32,000. Victory Capital Management Inc. boosted its position in shares of Heron Therapeutics by 30.2% during the fourth quarter. Victory Capital Management Inc. now owns 19,929 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 4,617 shares during the last quarter. ACT Advisors LLC. purchased a new stake in shares of Heron Therapeutics during the fourth quarter valued at $38,000. Finally, Diversified Trust Co purchased a new stake in shares of Heron Therapeutics during the first quarter valued at $66,000. 80.01% of the stock is owned by hedge funds and other institutional investors.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Stories
- Five stocks we like better than Heron Therapeutics
- ETF Screener: Uses and Step-by-Step Guide
- MarketBeat Week in Review – 6/10 – 6/14
- What is the Nikkei 225 index?
- Top 5 High-Performance Cryptocurrency ETFs to Watch
- Bank Stocks – Best Bank Stocks to Invest In
- 3 Stocks That Plummeted After the Post-Fed Speech Crash
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.